Breakthrough Protein Identified for Heart Failure Recovery After LVAD Treatment

The discovery of a protein linked to heart recovery represents a significant step forward in understanding and treating advanced heart failure. Researchers have identified PERM1 as a critical molecular factor in the recovery of heart function among patients receiving left ventricular assist devices (LVADs), offering new insights into why some hearts regain strength while others do not.

The study, published in the Journal of the American Heart Association, involved collaboration between Virginia Tech’s Fralin Biomedical Research Institute at VTC and the University of Utah. Led by cardiovascular molecular researcher Junco Warren and cardiologist Stavros Drakos, the research analyzed heart tissue from 19 patients undergoing LVAD treatment. These devices, which reduce strain on the heart by mechanically assisting blood flow, stabilize patients with advanced heart failure but only restore function in a subset of cases.

Before LVAD implantation, all patients exhibited reduced levels of PERM1, a protein involved in regulating energy production and cellular function in heart muscle cells. After treatment, PERM1 levels returned to near-normal only in patients whose hearts showed improved function. Non-responders maintained suppressed PERM1 levels, suggesting a direct correlation between the protein’s restoration, and recovery.

“This is the first muscle-specific molecular signal linked to recovery in human heart failure,” said Warren, assistant professor at the Fralin Biomedical Research Institute and co-corresponding author. The findings highlight PERM1’s potential as both a biomarker for predicting recovery and a target for therapeutic interventions.

Heart failure affects over 6 million people in the United States, with recovery remaining a complex and poorly understood challenge. Current treatments focus on managing symptoms rather than repairing damaged heart tissue. The study’s results point to a pathway that directly addresses two core deficits in heart failure: impaired energy production and weakened contractile function.

“PERM1 appears to act at the center of a vicious cycle where energy loss and reduced contraction reinforce each other,” Warren explained. Previous research from Warren’s lab demonstrated that increasing PERM1 improves heart function in experimental models, with findings showing the protein can prevent heart failure in preclinical studies.

The study’s authors emphasize that while PERM1’s role in recovery is promising, further research is needed to determine whether it drives the process or merely reflects it. “We don’t yet know whether PERM1 drives recovery or reflects it, but it gives us a clear window into the biology of how recovery happens,” Warren said.

The research team is advancing these discoveries through a startup focused on developing PERM1-based gene therapies. The project received support from the National Institutes of Health, the American Heart Association, the U.S. Department of Veterans Affairs, and the Nora Eccles Treadwell Foundation.

Drakos, professor of cardiology at the University of Utah and co-corresponding author, noted the importance of identifying biological signals behind recovery. “Understanding these mechanisms is essential to improving outcomes for patients with advanced heart failure,” he said.

The study’s methodology involved comparing heart tissue samples collected before and after LVAD implantation. Patients were categorized as responders or non-responders based on improvements in heart function. The team found that recovered hearts exhibited normalized stress-related metabolic pathways, a process regulated by PERM1.

While the findings offer hope, the researchers caution that the results are preliminary. “Current therapies help manage heart failure, but they do not repair the heart muscle itself,” Warren said. “Our findings point to a pathway that directly targets cardiomyocytes—the heart muscle cells—and restores both energy production and contractile function.”

The potential applications of this research extend beyond LVAD support. By targeting PERM1, future therapies could address heart failure at its molecular root, offering alternatives to mechanical devices and transplants. However, clinical trials and additional studies are required to validate these possibilities.

The study underscores the growing importance of molecular research in cardiology. As heart failure remains a leading cause of hospitalization and mortality, discoveries like PERM1’s role in recovery could reshape treatment paradigms. For patients with advanced heart failure, the ability to predict and enhance recovery represents a critical advancement in care.

For now, the research provides a foundation for further exploration. “This is just the beginning,” Warren said. “We are excited about the potential for PERM1 to transform how we approach heart failure treatment.”

The findings highlight the interplay between basic science and clinical care, demonstrating how molecular insights can inform patient outcomes. As the field of cardiology continues to evolve, the study of proteins like PERM1 may unlock new strategies for combating one of the most pressing health challenges of the 21st century.